CORPORATE HIGHLIGHTS

• Privately-held clinical stage Montreal-based biotechnology company
• Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets
• Currently, having one program with Phase I data
• Portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology
• Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline
• Established strategic partnerships to to access mAb generation, humanization, antibody drug conjugates, and CHO production technologies
• Seasoned management and multi-disciplinary discovery and early-stage development team
• Unencumbered pipeline with the potential for selected strategic partnerships on therapeutic mAbs